Newsroom

Jan 4, 2024

OnQuality Announces FDA Clearance of IND Application for OQL025 for the treatment of EGFR Inhibitor-Induced Acneiform Rash

View on PRNewswire SEATTLE, Jan. 4, 2024 /PRNewswire/ -- OnQuality Pharmaceuticals ("OnQuality"), a leading targeted oncology supportive...

Jun 6, 2023

View on PRNewswire SEATTLE, June 6, 2023 /PRNewswire/ -- OnQuality Pharmaceuticals ("OnQuality"), a targeted oncology supportive therapy...

Apr 28, 2023

View on PRNewswire SEATTLE, April 28, 2023 /PRNewswire/ -- OnQuality Pharmaceuticals ("OnQuality"), a targeted oncology supportive...

Apr 18, 2023

View on PRNewswire SEATTLE, April 18, 2023 /PRNewswire/ -- OnQuality Pharmaceuticals ("OnQuality"), a targeted oncology supportive...

Mar 15, 2023

View on PRNewswire SEATTLE, March 15, 2023 /PRNewswire/ -- OnQuality Pharmaceuticals ("OnQuality"), a targeted oncology supportive...

Jan 5, 2023

View on PR Newswire SEATTLE, Jan. 5, 2023 /PRNewswire/ -- OnQuality Pharmaceuticals ("OnQuality"), a targeted oncology supportive therapy...

Nov 10, 2022

Jordyn Sava November 10, 2022 Part 2 of the NOVA-II phase 2 trial evaluating OQL011 has enrolled the first patient with cancer with...

Nov 9, 2022

November 9, 2022 The key objectives include the assessment of the efficacy and safety of OQL011 and the identification of an optimal...

Nov 8, 2022

View on PR Newswire SEATTLE, Nov. 8, 2022 /PRNewswire/ -- OnQuality Pharmaceuticals ("OnQuality"), a targeted oncology supportive...

Oct 13, 2022

Preclinical toxicology and pharmacology data demonstrating OQL051, a gut-restricted CDK4/6 inhibitor, as a potential prophylactic...